Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a

Journal of Viral Hepatitis

Volumn 18, Issue 8, 2011, Pages 595-600

  Zhou, Y Q ^a,b   Wang, X H ^a   Hong, G H ^a   Zhu, Y ^a   Zhang, X Q ^a   Hu, Y J ^a   Mao, Q ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b The 169th Hospital of Chinese People's Liberation Army   (China)

Author keywords

China; genotype; hepatitis C; treatment outcome

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; CHINA; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; POLYETHYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 79960667826     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01373.x     Document Type: Article

References (22)

1. Pang PS, Planet PJ, Glenn JS,. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS ONE 2009; 4: e6579.
2. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47: 43-50. (Pubitemid 351171040)
3. Nguyen MH, Keeffe EB,. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3: S97-S101. (Pubitemid 41427738)
4. Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2009; 30 (3): 342-355.
5. Antaki N, Marcellin P,. What is the safe duration of therapy for patients infected with HCV genotype 6? Nat Clin Pract Gastroenterol Hepatol 2009; 6: 78-79.
6. Lwin AA, Shinji T, Khin M, et al. Hepatitis C virus genotype distribution in Myanmar: predominance of genotype 6 and existence of new genotype 6 subtype. Hepatol Res 2007; 37: 337-345. (Pubitemid 46605418)
7. Fung J, Lai CL, Hung I, et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008; 198: 808-812.
8. Xia X, Lu L, Tee KK, et al. The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. J Med Virol 2008; 80: 1142-1152. (Pubitemid 351705992)
9. Oh HB, Kim SO, Cha CH, et al. Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5' untranslated region using a matrix assisted laser desorption/ionization time of flight-based assay, restriction fragment mass polymorphism. J Med Virol 2008; 80: 1712-1719.
10. Lee YM, Lin HJ, Chen YJ, et al. Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: full-length sequences of two new subtype 6w strains and a recombinant form-2b6w. J Med Virol 2010; 82: 57-68.
11. Fu Y, Wang Y, Xia W, et al. New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors. J Viral Hepat 2010; doi: 10.1111/j.1365-2893.2010.01280.x.
12. Nguyen NH, Vutien P, Garcia RT, et al. Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6. J Viral Hepat 2010; 17 (10): 691-697.
13. Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL,. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003; 187: 1071-1074. (Pubitemid 36399349)
14. Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB,. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008; 103: 1131-1135. (Pubitemid 351677993)
15. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W,. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002; 36: 1259-1265. (Pubitemid 35253444)
16. Poordad FF, Review article: the role of rapid virologic response in determining treatment duration for chronic hepatitis C. Aliment Pharmacol Ther 2010; 31 (12): 1251-1267.
17. Ide T, Hino T, Ogata K, et al. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol 2009; 104: 70-75.
18. Zhou Y, Wang X, Mao Q, et al. Changes in modes of hepatitis C infection acquisition and genotypes in southwest China. J Clin Virol 2009; 46: 230-233.
19. Giannini EG, Basso M, Savarino V, Picciotto A,. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31 (4): 502-508.
20. Bizollon T, Ahmed SN, Radenne S, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283-287. (Pubitemid 36115073)
21. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
22. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.